Skip to main content
Equibles
BBOT logo

BBOT · BridgeBio Oncology Therapeutics, Inc. · Metrics

Track BBOT — free

Use BBOT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BBOT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$4.95 -0.57 (-10.33%) At close · Sep 11
Rebalance outlook locked
Market Cap
$399.67M
Shares
80.17M

BBOT metrics

58 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$4.95
Market cap
$399.67M

Price action

20 metrics
Price change (1W)
-38.0%
Price change (30D)
-40.2%
Price change (3M)
-26.0%
Price change (6M)
-39.5%
Price change (YTD)
-55.9%
Price change (1Y)
-45.1%
Trailing year
Price change (5Y)
—
52-week high
$13.73
52-week low
$5.52
Change from 52-week high
-59.8%
Change from 52-week low
+0.0%
Annualized volatility
69.2%
Annualized volatility (3M)
79.8%
Beta
1.6
RSI (14D)
18.8
Price vs SMA 50
-36.5%
Price vs SMA 200
-43.0%
Avg volume (3M)
427,900
Relative volume
6.5
Average dollar volume
$3.41M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
80.17M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
1.2
reciprocal yield 80.8%
FCF yield
-37.9%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-45.6%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-01-07

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$198.96M
Net income (TTM)
−$182.11M
Trailing 12 months
Diluted EPS (TTM)
$-1,232.83
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-579.43
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-528.33
Operating cash flow per diluted share (TTM)
$-450.53
Free cash flow per diluted share (TTM)
$-450.83
Capital expenditures per diluted share (TTM)
$0.30
R&D per diluted share (TTM)
$499.22
Stock compensation per diluted share (TTM)
$48.54
Book value per share
$5.14

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+59.5%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-56.4%
Return on assets
-48.3%
Debt / equity
—
Current ratio
4.7
EBITDA (TTM)
—
Free cash flow (TTM)
−$151.56M
Quick ratio
4.7
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$225.71M
Latest balance sheet
Cash & equivalents
$54.06M
Total assets
$376.71M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$151.28M
Capital expenditures (TTM)
$284,000
R&D (TTM)
$162.15M
SG&A (TTM)
—
Stock compensation (TTM)
$16.31M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
65
13F filer change QoQ
-2
Institutional ownership
73.7%

Short interest

3 metrics
Short interest
7.7%
Latest settlement · 20.8 days to cover
Days to cover
20.8d
Short-squeeze score
61 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1869105 CUSIP 107924102 13F (30d) 51 filings 51 filers Visit website Investor relations